PhaseⅡclinical trial of raltitrexed plus oxaliplatin combined with concurrent radiotherapy for advanced esophageal carcinoma
10.3969/j.issn.1000-8179.20140440
- VernacularTitle:放疗联合雷替曲塞奥沙利铂同步治疗中晚期食管癌的Ⅱ期临床研究
- Author:
XIA Youyou
;
WANG Lei
;
SONG Da'an
;
LI Shiqiu
;
JIANG Xiaodong
- Publication Type:Journal Article
- Keywords:
esophageal carcinoma;
raltitrexed plus oxaliplatin;
radiotherapy;
concurrent therapy;
prognosis
- From:
Chinese Journal of Clinical Oncology
2014;45(11):716-719
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of raltitrexed plus oxaliplatin combined with concurrent radiotherapy for advanced esophageal carcinoma. Methods:A total of 54 patients with stageⅡ/Ⅲadvanced esophageal carcinoma according to the clinical staging of esophageal carcinoma nonsurgical methods were treated with raltitrexed plus oxaliplatin combined with concurrent radiotherapy. The patients were irradiated with a dose of 60 Gy in 30 fractions. Two cycles of concurrent chemotherapy were adminis-tered during radiotherapy, with 100 mg/m2 oxaliplatin and 2.6 mg/m2 raltitrexed on d1 and d22. Results:The complete response rate was 16.7%(9/54), and the partial response rate was 68.5%(37/54). The total response rate was 85.2%. The no response and progression rate was 14.8%(8/54). The one-and two-year local control rates and overall survival rates were 75.4%, 57.3%and 70.4%(95%CI, 0.6-0.8), 46.6%(95%CI, 0.3-0.6), respectively. The incidence rates of radiation-induced esophagitis, leucopenia, acute diarrhea, neuro-toxicity were 100%, 72.2%, 16.7%, and 44.4%, of which 7.4%, 7.4%, 1.9%, and 0%were≥grade 3, respectively. Conclusion:Ralti-trexed plus oxaliplatin combined with concurrent radiotherapy can enhance the response rate and prolong the survival of patients with advanced esophageal carcinoma. The regime has mild toxicity and is worthy of further study in PhaseⅢ.
